drugset / Trial / NCT00948389
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Phase 1/2
Terminated
28 enrolled
Bristol-Myers Squibb
European Organisation for Research and Treatment of Cancer - EORTC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
Timeline
- Start
- 2009-10
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lomustine | Small molecule | 110 mg/m2 | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |